Literature DB >> 10983196

Large-scale hormone replacement therapy and life expectancy: results from an international comparison among European and North American populations.

S Panico1, R Galasso, E Celentano, A V Ciardullo, L Frova, R Capocaccia, M Trevisan, F Berrino.   

Abstract

OBJECTIVES: An analysis was performed to determine the risks and benefits of a 10-year hormone replacement therapy regimen that had been applied to all women at 50 years of age in 8 countries.
METHODS: Cumulative mortality with and without hormone replacement therapy over 20 years was estimated, with both current and predicted total and disease-specific secular mortality trends and the influence of a generational cohort effect taken into account.
RESULTS: In countries with high ischemic heart disease frequency and predictable relative predominance of ischemic heart disease rates over breast cancer rates for the next 20 years, hormone replacement therapy could result in benefits with regard to overall mortality; this advantage decreases in younger-generation cohorts. In countries in which breast cancer mortality predominates over ischemic heart disease in early postmenopause and in which the predictable trends for both diseases reinforce this condition, a negative effect on overall mortality would be observed. In the United States, the effect of large-scale hormone replacement therapy would change over time.
CONCLUSIONS: The long-term effect of hormone replacement therapy on life expectancy of postmenopausal women may vary among countries.

Entities:  

Mesh:

Year:  2000        PMID: 10983196      PMCID: PMC1447610          DOI: 10.2105/ajph.90.9.1397

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  40 in total

1.  Age, period, cohort and early mortality: an analysis of adult mortality in Italy.

Authors:  G Caselli; R Capocaccia
Journal:  Popul Stud (Camb)       Date:  1989-03

2.  Estrogen replacement therapy and breast cancer survival in a large screening study.

Authors:  C Schairer; M Gail; C Byrne; P S Rosenberg; S R Sturgeon; L A Brinton; R N Hoover
Journal:  J Natl Cancer Inst       Date:  1999-02-03       Impact factor: 13.506

3.  Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials.

Authors:  E Hemminki; K McPherson
Journal:  BMJ       Date:  1997-07-19

4.  Estimating the completeness of prevalence based on cancer registry data.

Authors:  R Capocaccia; R De Angelis
Journal:  Stat Med       Date:  1997-02-28       Impact factor: 2.373

5.  Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study.

Authors:  D L Schneider; E L Barrett-Connor; D J Morton
Journal:  JAMA       Date:  1997-02-19       Impact factor: 56.272

6.  Hormone replacement therapy and early clinical appearance of low grade breast cancer.

Authors:  F Berrino; S Panico
Journal:  Cancer Causes Control       Date:  1997-07       Impact factor: 2.506

7.  Postmenopausal hormone therapy and mortality.

Authors:  F Grodstein; M J Stampfer; G A Colditz; W C Willett; J E Manson; M Joffe; B Rosner; C Fuchs; S E Hankinson; D J Hunter; C H Hennekens; F E Speizer
Journal:  N Engl J Med       Date:  1997-06-19       Impact factor: 91.245

8.  Patient-specific decisions about hormone replacement therapy in postmenopausal women.

Authors:  N F Col; M H Eckman; R H Karas; S G Pauker; R J Goldberg; E M Ross; R K Orr; J B Wong
Journal:  JAMA       Date:  1997-04-09       Impact factor: 56.272

9.  Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States.

Authors:  D B Willis; E E Calle; H L Miracle-McMahill; C W Heath
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

10.  Prognostic characteristics in breast cancers after hormone replacement therapy.

Authors:  C Magnusson; L Holmberg; T Nordén; A Lindgren; I Persson
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

View more
  1 in total

1.  The risk of bias from omitted research.

Authors:  S Garattini; A Liberati
Journal:  BMJ       Date:  2000-10-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.